About Zobio Zobio Drug Discovery Technology Zobio will join forces with oncodesign services (ods), a leading contract research organization (cro) specializing in drug discovery and preclinical services with notable expertise in oncology and immuno inflammation. Dijon, france & leiden, the netherlands, january 23rd, 2024 – oncodesign services (ods) announces its international expansion through the acquisition of zobio, a dutch cro expert in biophysics based small molecule drug discovery.
Capabilities Zobio Drug Discovery Technology Jean françois félix and maxence de vienne, partners at elyan: « the acquisition of zobio reflects the ambition that we share with the management team of oncodesign services to build a european leader in preclinical services. Broadoak capital partners advised zobio on the sale of the company to oncodesign services. zobio is a leading provider of biophysics based small molecule drug discovery services. Oncodesign services, a french oncology specialist that provides clinical services, has acquired dutch cro zobio for an undisclosed price. zobio, which was founded almost two decades ago,. Nnounces its international expansion through the acquisition of zobio, a dutch cro expert in biophysics based small molecule drug discovery. this acquisition allows ods to strengthen and extend its expertise and capabilities in the field of small mol.
Events Zobio Drug Discovery Technology Oncodesign services, a french oncology specialist that provides clinical services, has acquired dutch cro zobio for an undisclosed price. zobio, which was founded almost two decades ago,. Nnounces its international expansion through the acquisition of zobio, a dutch cro expert in biophysics based small molecule drug discovery. this acquisition allows ods to strengthen and extend its expertise and capabilities in the field of small mol. With this transaction, ods and zobio jointly represent nearly 280 employees spread across dijon and les ulis in france, leiden in netherlands and with subsidiaries in canada and the united states. Oncodesign services (ods) is a leading cro specializing in drug discovery and preclinical services. it contributes to the development of innovative therapies in oncology, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, dmpk, pharmaco imaging, bioanalysis, and in vivo in vitro pharmacology. Zobio provides a complete solution for fragment based drug discovery to our clients. zobio is based in leiden, france. Oncodesign services (ods), a leading contract research organization specialized in drug discovery and preclinical services, has announced its acquisition of zobio, a dutch cro expert in biophysics based small molecule drug discovery.
Comments are closed.